All News

Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months

The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.

More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.

This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.

New results show that non-Hispanic Black patients with COVID-19 and type 1 diabetes have an additional risk of diabetic ketoacidosis beyond the risk of having diabetes or being of minority status.

Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.

Use basic knowledge of medications to be the first line of defense in ensuring safety and maintaining pharmacy workflow.

Among surveyed American adults, more than half were diagnosable with probable depression at baseline, in addition to 65% who had anxiety and 51% at risk for post-traumatic stress disorder.

Exposure to fine particulate, carbon monoxide, and ozone over time was linked to increased methylation, leading to higher rates of heart disease and other conditions in adulthood.

When analyzing the odds of death or hospitalization due to COVID-19, the researchers found that use of cytotoxic chemotherapy did not predict increased risk for either.

The researchers analyzed body composition data from the National Health and Nutrition Examination Survey (1999-2004) and cardiovascular disease data from the National Health and Nutrition Examination Survey (1999-2014).

The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.

Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.

Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate in combination with a pandemic adjuvant commenced following approval to proceed with participant enrollment from regulatory authorities in both Canada and the United States.

Investigators found a statistically significant improvement in both overall survival and progression-free survival for patients who received pembrolizumab with chemotherapy.

Intranasal administration of virucidal and antiviral therapies may provide added clinical benefit by decreasing viral activity in the nasal pathway, preventing COVID-19 transmission and managing disease severity.

Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.

The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regard to naloxone.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.

This was the first genome-wide association study of skin pigmentation in African Americans, according to the study authors.

Clinicians have been searching for accurate, reliable, non-invasive diagnostic tools to differentiate early stage, less dangerous, and more treatable stages of the disease from the aggressive, high-grade and likely-to-spread forms.

The independent data safety monitoring board conducted a specific review of thrombotic events related to AstraZeneca’s COVID-19 vaccine and found no increased risk.

Black adults living in rural areas of the United States have experienced higher mortality rates due to diabetes, hypertension, heart disease, and stroke compared to white adults over the past 20 years, according to a research letter published in the Journal of the American College of Cardiology.

Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists can be first line in noticing changes in patients’ cognitive functioning.

The first participants were dosed in the phase 2/3 KidCOVE study investigating vaccine candidate mRNA-1273 against COVID-19 in children aged 6 months to less than 12 years of age.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The findings reveal a unique mechanism for C.diff survival in the human gut and suggest novel strategies for weakening its defenses, according to the study authors.

The research demonstrates that the coronavirus enzyme PLpro physically interacts with the receptor MDA5 and inhibits the ISGylation process.